CN101528707B - 用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物 - Google Patents
用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物 Download PDFInfo
- Publication number
- CN101528707B CN101528707B CN2007800392434A CN200780039243A CN101528707B CN 101528707 B CN101528707 B CN 101528707B CN 2007800392434 A CN2007800392434 A CN 2007800392434A CN 200780039243 A CN200780039243 A CN 200780039243A CN 101528707 B CN101528707 B CN 101528707B
- Authority
- CN
- China
- Prior art keywords
- ethyl
- methyl
- alpha
- fluorophenyl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C1)(C(CCc2ccccc2*)(CC2)O)C2=Cc2c1cn[n]2-c(cc1)ccc1F Chemical compound CC(C1)(C(CCc2ccccc2*)(CC2)O)C2=Cc2c1cn[n]2-c(cc1)ccc1F 0.000 description 5
- WLCMNPGGEITDNK-UHFFFAOYSA-N CC(C1)(C(CCc2c(C(C(N)=O)O)cccc2)(CC2)O)C2=Cc2c1cn[n]2-c(cc1)ccc1F Chemical compound CC(C1)(C(CCc2c(C(C(N)=O)O)cccc2)(CC2)O)C2=Cc2c1cn[n]2-c(cc1)ccc1F WLCMNPGGEITDNK-UHFFFAOYSA-N 0.000 description 1
- LKAARZBOQKILMB-UHFFFAOYSA-N CCNC(NCc1c(CCC2(C3)OCCC2=Cc2c3cn[n]2-c(cc2)ccc2F)cccc1)=O Chemical compound CCNC(NCc1c(CCC2(C3)OCCC2=Cc2c3cn[n]2-c(cc2)ccc2F)cccc1)=O LKAARZBOQKILMB-UHFFFAOYSA-N 0.000 description 1
- VBMMKCSBWPIMOY-UHBYFKDRSA-N CCO[C@@](CCc1c(CN(C(c2c3cccc2)=O)C3=O)cccc1)(CC1)C(C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F Chemical compound CCO[C@@](CCc1c(CN(C(c2c3cccc2)=O)C3=O)cccc1)(CC1)C(C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F VBMMKCSBWPIMOY-UHBYFKDRSA-N 0.000 description 1
- NBMFADPFBYYSMM-UHFFFAOYSA-N CNCc1c(CCC2(C3)OCCC2=Cc2c3cn[n]2-c(cc2)ccc2F)cccc1 Chemical compound CNCc1c(CCC2(C3)OCCC2=Cc2c3cn[n]2-c(cc2)ccc2F)cccc1 NBMFADPFBYYSMM-UHFFFAOYSA-N 0.000 description 1
- OVNNQSKNCOQZQG-UHFFFAOYSA-N OC(c1c(CCC2(C3)OCCC2=CC(C2)=C3C=NC2c(cc2)ccc2F)cccc1)=O Chemical compound OC(c1c(CCC2(C3)OCCC2=CC(C2)=C3C=NC2c(cc2)ccc2F)cccc1)=O OVNNQSKNCOQZQG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Description
行 | 试剂 | FW | 量 | mMol |
1 | 炔4 | 308.35 | 9.87gA | 32.0 |
2 | 溴化物5 | 218.02 | 7.67g | 35.2 |
3 | 哌啶 | 85.15 | 6.39mL | 64.0 |
4 | [(烯丙基)PdCl]2 | 365.89 | 58.8mgA | 0.160 |
5 | (t-Bu)3P.HBF4 | 290.13 | 232mgA | 0.800 |
6 | CH3CN | 41.05 | 50mL | |
8 | 甲苯 | 92.14 | 100mL |
Claims (20)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85365506P | 2006-10-23 | 2006-10-23 | |
US60/853,655 | 2006-10-23 | ||
US92333707P | 2007-04-13 | 2007-04-13 | |
US60/923,337 | 2007-04-13 | ||
PCT/US2007/022463 WO2008051532A1 (en) | 2006-10-23 | 2007-10-23 | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101528707A CN101528707A (zh) | 2009-09-09 |
CN101528707B true CN101528707B (zh) | 2012-11-07 |
Family
ID=39030900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800392434A Expired - Fee Related CN101528707B (zh) | 2006-10-23 | 2007-10-23 | 用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8119681B2 (zh) |
EP (2) | EP2091922B1 (zh) |
JP (1) | JP5271911B2 (zh) |
KR (1) | KR20090068345A (zh) |
CN (1) | CN101528707B (zh) |
AT (1) | ATE538099T1 (zh) |
AU (1) | AU2007309507A1 (zh) |
BR (1) | BRPI0718505A2 (zh) |
CA (1) | CA2667007A1 (zh) |
CO (1) | CO6190517A2 (zh) |
CR (1) | CR10771A (zh) |
EA (1) | EA200970401A1 (zh) |
IL (1) | IL198226A0 (zh) |
MA (1) | MA30870B1 (zh) |
MX (1) | MX2009004385A (zh) |
NO (1) | NO20092004L (zh) |
SV (1) | SV2009003233A (zh) |
TN (1) | TN2009000149A1 (zh) |
WO (2) | WO2008060391A2 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
EP2532350A1 (en) * | 2007-10-17 | 2012-12-12 | Laboratoire HRA Pharma | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
US20100228036A1 (en) * | 2007-10-23 | 2010-09-09 | Qinghao Chen | Process for making glucocorticoid receptor ligands |
TWI445705B (zh) | 2008-05-20 | 2014-07-21 | Astrazeneca Ab | 經苯基及苯并二基取代之吲唑衍生物 |
WO2010138421A1 (en) * | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
US20120095055A1 (en) | 2009-06-02 | 2012-04-19 | Merck Sharp & Dohme, Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
WO2011031574A1 (en) * | 2009-09-08 | 2011-03-17 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
US20120214847A1 (en) * | 2009-10-30 | 2012-08-23 | Merck Sharp & Dohme Corp. | 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
CA2860323C (en) | 2011-12-28 | 2022-03-08 | The Regents Of The University Of California | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
PE20201444A1 (es) | 2014-02-07 | 2020-12-10 | Global Blood Therapeutics Inc | Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
EP3335043B1 (en) | 2015-08-13 | 2021-03-31 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
EP3405101B1 (en) | 2016-01-19 | 2020-12-23 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US10195214B2 (en) | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
EP3972963A1 (en) | 2019-05-21 | 2022-03-30 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846839B1 (en) * | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
JP4745609B2 (ja) * | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
US7411073B2 (en) * | 2003-02-25 | 2008-08-12 | Merck & Co., Inc. | Selective non-steroidal glucocorticoid receptor modulators |
DE602004023926D1 (de) * | 2003-04-23 | 2009-12-17 | Merck & Co Inc | Selektive spirocyclische glucocorticoid-rezeptor-modulatoren |
-
2007
- 2007-10-23 CN CN2007800392434A patent/CN101528707B/zh not_active Expired - Fee Related
- 2007-10-23 KR KR1020097008368A patent/KR20090068345A/ko not_active Application Discontinuation
- 2007-10-23 WO PCT/US2007/022449 patent/WO2008060391A2/en active Application Filing
- 2007-10-23 CA CA002667007A patent/CA2667007A1/en not_active Abandoned
- 2007-10-23 US US12/445,901 patent/US8119681B2/en not_active Expired - Fee Related
- 2007-10-23 AT AT07867264T patent/ATE538099T1/de active
- 2007-10-23 JP JP2009534622A patent/JP5271911B2/ja not_active Expired - Fee Related
- 2007-10-23 WO PCT/US2007/022463 patent/WO2008051532A1/en active Application Filing
- 2007-10-23 EP EP07867264A patent/EP2091922B1/en not_active Withdrawn - After Issue
- 2007-10-23 EA EA200970401A patent/EA200970401A1/ru unknown
- 2007-10-23 AU AU2007309507A patent/AU2007309507A1/en not_active Abandoned
- 2007-10-23 BR BRPI0718505-7A patent/BRPI0718505A2/pt not_active Application Discontinuation
- 2007-10-23 MX MX2009004385A patent/MX2009004385A/es unknown
- 2007-10-23 EP EP07839748A patent/EP2097385B1/en active Active
-
2009
- 2009-04-19 IL IL198226A patent/IL198226A0/en unknown
- 2009-04-21 TN TNP2009000149A patent/TN2009000149A1/fr unknown
- 2009-04-21 SV SV2009003233A patent/SV2009003233A/es not_active Application Discontinuation
- 2009-04-22 CO CO09040679A patent/CO6190517A2/es not_active Application Discontinuation
- 2009-05-06 CR CR10771A patent/CR10771A/es not_active Application Discontinuation
- 2009-05-07 MA MA31847A patent/MA30870B1/fr unknown
- 2009-05-22 NO NO20092004A patent/NO20092004L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR10771A (es) | 2009-05-25 |
IL198226A0 (en) | 2009-12-24 |
CO6190517A2 (es) | 2010-08-19 |
MX2009004385A (es) | 2009-05-22 |
ATE538099T1 (de) | 2012-01-15 |
CN101528707A (zh) | 2009-09-09 |
EP2091922B1 (en) | 2011-12-21 |
EP2097385B1 (en) | 2012-08-01 |
WO2008051532A1 (en) | 2008-05-02 |
TN2009000149A1 (en) | 2010-10-18 |
BRPI0718505A2 (pt) | 2013-11-12 |
WO2008060391A2 (en) | 2008-05-22 |
JP5271911B2 (ja) | 2013-08-21 |
US8119681B2 (en) | 2012-02-21 |
WO2008060391A3 (en) | 2008-09-25 |
US20100311709A1 (en) | 2010-12-09 |
KR20090068345A (ko) | 2009-06-26 |
EP2091922A2 (en) | 2009-08-26 |
NO20092004L (no) | 2009-07-22 |
SV2009003233A (es) | 2009-10-19 |
MA30870B1 (fr) | 2009-11-02 |
JP2010507663A (ja) | 2010-03-11 |
CA2667007A1 (en) | 2008-05-02 |
AU2007309507A1 (en) | 2008-05-02 |
EA200970401A1 (ru) | 2009-10-30 |
EP2097385A1 (en) | 2009-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101528707B (zh) | 用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物 | |
CN105073738B (zh) | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 | |
CN101460466B (zh) | 适用作蛋白激酶抑制剂的噻唑类、咪唑类和吡唑类 | |
CN104788427B (zh) | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 | |
CN102271682A (zh) | 用于治疗疼痛的p2x3受体拮抗剂 | |
CN102224142B (zh) | 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物 | |
CN105753814A (zh) | 取代氮杂环衍生物及其应用 | |
CA2978823A1 (en) | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | |
KR20150130415A (ko) | 질환의 치료에 유용한 헤테로환식 화합물 | |
MX2007016319A (es) | Derivados de n-(piridin-2-il)-sulfonamida. | |
AU2006237365A1 (en) | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 | |
CN103772299A (zh) | 新型哌嗪酰胺衍生物 | |
CN103159738A (zh) | 炔基桥连的杂芳香化合物及其应用 | |
AU2009217493B2 (en) | Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators | |
NZ521060A (en) | Pharmaceutically active pyrrolidine derivatives as bax inhibitors and method of preparation thereof | |
CN106068263A (zh) | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 | |
CN107922422A (zh) | TGFβ受体拮抗剂 | |
EP2265273B1 (en) | Hexahydrocyclopentyl[f] indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators | |
TW201823236A (zh) | 聯芳組成物和調控激酶級聯之方法 | |
CN105228609A (zh) | 新的转录因子调节剂 | |
WO2018068357A1 (zh) | 一类新型sirt2蛋白抑制剂及其在制药中的用途 | |
JP4414219B2 (ja) | C−jun−n−末端キナーゼ(jnk)インヒビターとしてのアリールスルホンアミド誘導体 | |
CN106543088B (zh) | 一类sirt2蛋白抑制剂及其在制药中的用途 | |
WO2022017524A1 (zh) | 吡啶酮类化合物及其制备方法和应用 | |
TW202406903A (zh) | 聯芳組成物和調控激酶級聯之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121031 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Address before: New jersey, USA Patentee before: SCHERING Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121031 Address after: New jersey, USA Patentee after: SCHERING Corp. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20131023 |